Vonoprazan: First Global Approval

被引:117
作者
Garnock-Jones, Karly P. [1 ]
机构
[1] Springer, Auckland 0754, New Zealand
关键词
COMPETITIVE ACID BLOCKER; MONOFUMARATE TAK-438;
D O I
10.1007/s40265-015-0368-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vonoprazan (Takecab((R))) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication. Phase III development is underway for the prevention of recurrence of duodenal and gastric ulcer in patients receiving aspirin or NSAID therapy. Phase I development was conducted in the UK for gastro-oesophageal reflux; however, no further development has been reported. This article summarizes the milestones in the development of vonoprazan leading to this first approval for acid-related diseases.
引用
收藏
页码:439 / 443
页数:5
相关论文
共 12 条
[1]   Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB) [J].
Arikawa, Yasuyoshi ;
Nishida, Haruyulci ;
Kurasawa, Osamu ;
Hasuoka, Atsushi ;
Hirase, Keizo ;
Inatomi, Nobuhiro ;
Hori, Yasunobu ;
Matsukawa, Jun ;
Imanishi, Akio ;
Kondo, Mitsuyo ;
Tarui, Naoki ;
Hamada, Teruki ;
Takagi, Terufumi ;
Takeuchi, Toshiyuki ;
Kajino, Masahiro .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (09) :4446-4456
[2]  
Chiba T, 2013, GASTROENTEROLOGY S1, V144, pS
[3]   1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases [J].
Hori, Yasunobu ;
Imanishi, Akio ;
Matsukawa, Jun ;
Tsukimi, Yasuhiro ;
Nishida, Haruyuki ;
Arikawa, Yasuyoshi ;
Hirase, Keizo ;
Kajino, Masahiro ;
Inatomi, Nobuhiro .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (01) :231-238
[4]  
Iwakiri K, 2014, GASTROENTEROLOGY, V146, pS741
[5]  
Kawai T, 2014, GASTROENTEROLOGY, V146, pS739
[6]   Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers [J].
Luo, Hua-Jun ;
Deng, Wei-Qiao ;
Zou, Kun .
PLOS ONE, 2014, 9 (05)
[7]  
Mizokami Y, 2014, GASTROENTEROLOGY, V146, pS739
[8]  
Murakami K, 2014, HELICOBACTER, V19, P79
[9]  
Murakami K, 2014, GASTROENTEROLOGY, V146, pS740
[10]   Novel approaches to inhibition of gastric acid secretion [J].
Sachs G. ;
Shin J.M. ;
Hunt R. .
Current Gastroenterology Reports, 2010, 12 (6) :437-447